• Skip to main content

DistilINFO LifeSciences

Weekly round up from Life Sciences Industry.

  • Publications
    • Home
    • DistilINFO HealthPlan
    • DistilINFO HospitalIT
    • DistilINFO IT
    • DistilINFO Retail
    • DistilINFO POPHealth
    • DistilINFO Ageing
    • DistilINFO Life Sciences
    • DistilINFO GovHealth
    • DistilINFO EHS
    • DistilINFO HealthIndia
    • Subscribe
    • Submit Article
    • Advertise
    • Newsletters

USD Partners Divests Casper Rail Terminal for $33M to South 49

Share:

March 27, 2023

USD Partners (NYSE:USDP) has announced that it will sell its Casper rail terminal to South 49 Holdings for approximately $33 million. The transaction is expected to be completed before the end of the second quarter of 2023. USD Partners plans to use most of the proceeds from the sale to pay off its revolving credit facility’s outstanding borrowings and for general partnership purposes.

  • USD Partners (NYSE:USDP) said Thursday it will sell its Casper rail terminal to South 49 Holdings.
  • The sale price for the rail terminal was about $33.0 million.
  • The transaction is expected to close prior to the end of the second quarter of 2023.
  • The partnership said it intends to use a majority of the proceeds from the sale of the terminal to repay borrowings outstanding under its revolving credit facility, general partnership purposes.

 

Source: SeekingAlpha

Coffee with DistilINFO's Morning Updates...

Sign up for DistilINFO e-Newsletters.

Just a little bit more about you...
PROCEED
Choose Lists
BACK

Related Stories

  • It’s a Wrap! Takeda-Shire Merger Is a Done Deal, Making Takeda the Largest Mass. Biotech EmployerIt’s a Wrap! Takeda-Shire Merger Is a Done Deal, Making Takeda the Largest Mass. Biotech Employer
  • ALSA Ventures Closes US$59 Million European Biotech Venture Capital FundALSA Ventures Closes US$59 Million European Biotech Venture Capital Fund
  • Getinge to Acquire Applikon Biotechnology B.V., A Leading Company in the Fast Growing Area of Bioreactor SystemsGetinge to Acquire Applikon Biotechnology B.V., A Leading Company in the Fast Growing Area of Bioreactor Systems
  • Atai Life Sciences Takes on Opioid Crisis By Acquiring Kures to Develop Novel Therapeutics for Opioid AbuseAtai Life Sciences Takes on Opioid Crisis By Acquiring Kures to Develop Novel Therapeutics for Opioid Abuse
  • Omada Becomes First NCQA-Accredited Virtual ProviderOmada Becomes First NCQA-Accredited Virtual Provider
  • InMed Pharmaceuticals Signs Definitive Agreement to Acquire BayMedica, a Leading Commercial Manufacturer of Rare CannabinoidsInMed Pharmaceuticals Signs Definitive Agreement to Acquire BayMedica, a Leading Commercial Manufacturer of Rare Cannabinoids
  • Biogen to Expand Biosimilars Portfolio and Gain Access to Additional Markets Through New Transaction with Samsung BioepisBiogen to Expand Biosimilars Portfolio and Gain Access to Additional Markets Through New Transaction with Samsung Bioepis
  • XRHealth to Deliver VR Therapy to Coronavirus Patients in Quarantine in IsraelXRHealth to Deliver VR Therapy to Coronavirus Patients in Quarantine in Israel

Trending This Week

Sorry. No data so far.

About Us

DistilINFO is media company that publishes Industry news, views and Interviews. We distil the information for you – saving time and keeping you up to date on your interest areas.

More About Us

Follow Us


Useful Links

  • Subscribe
  • Contact
  • Advertise
  • Privacy Policy
  • Terms of Service
  • Feedback

All Publications

  • DistilINFO HealthPlan Advisory
  • DistilINFO HospitalIT Advisory
  • DistilINFO IT Advisory
  • DistilINFO Retail Advisory
  • DistilINFO POPHealth Advisory
  • DistilINFO Ageing Advisory
  • DistilINFO Life Sciences Advisory
  • DistilINFO GovHealth Advisory
  • DistilINFO EHS Advisory
  • DistilINFO HealthIndia Advisory

© DistilINFO Publications